Cite
HARVARD Citation
Liu, G. et al. (2022). A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects. Expert opinion on biological therapy. pp. 187-195. [Online].